SAGE Therapeutics (SAGE) Misses Q3 EPS by 69c

SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($3.37), $0.69 worse than the analyst estimate of ($2.68). Revenue for the quarter came in at $2.72 million versus the consensus estimate of $4.63 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating